Ligand Pharmaceuticals Company Description
Ligand Pharmaceuticals is receptive to new ideas. The drug development company works with gene transcription technology to address assorted illnesses. The company sold off its commercial operations, including its FDA-approved pain drug Avinza, and has refocused on developing a pipeline of new compounds. Its research and development projects include treatments for thrombocytopenia (low platelet count), osteoporosis, menopausal conditions, hepatitis C, cancers, and chronic liver disease, developed internally and in collaboration with larger drug companies. Ligand is expanding its development pipeline through acquisitions.
View the Comprehensive Company Description for Ligand Pharmaceuticals
The Company Description provides a historical perspective of Ligand Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Ligand Pharmaceuticals's evolution in the marketplace.
